Mcgraw Benjamin F III reported grant involving 37,960 derivative units of Evommune, Inc. on Nov 13, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Nov 17, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
—Shares × reported price
Shares traded
37,960Stock Option (Right to buy)
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
37,960Direct
Trade date
Nov 13, 2026Grant
Filed
Nov 17, 2026, 4:40 PM ET4-day reporting delay
Accession
0001216994-26-000005Code A · Transaction 403782
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 13, 2026Grant15,673——Trade 403784
Nov 13, 2026Disposition to issuer37,960——Trade 403781
Nov 13, 2026Disposition to issuer15,673——Trade 403783
4 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

EVMN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
EVMN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −24%1w ago −13%1d ago +5.1%
Returns since7d30d90d180d1y

Footnotes in full

F1: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 5, 2025 and is partially vested. F2: The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; and (ii) a Change in Control during the Reporting Person's Continuous Service, each as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option. F3: One third (1/3) of the shares subject to the option award vested on November 5, 2026 and the remaining shares subject to the option shall vest in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. F4: The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 2, 2026. F5: The shares subject to the option award shall vest at the earlier of (i) June 2, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.